[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$1578b](/topic/$1578b) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "ABBVIE Q3 2025: ADJUSTED EPS $XXXX ON $15.78B REVENUE; RINVOQ AND SKYRIZI DRIVE GROWTH HUMIRA SALES FALL ON LOSS OF EXCLUSIVITY; FY2025 ADJUSTED EPS GUIDANCE RAISED TO $10.61-$10.65" [X Link](https://x.com/MultibaggAIUS/status/1984374282320060476) [@MultibaggAIUS](/creator/x/MultibaggAIUS) 2025-10-31T21:37Z XX followers, XX engagements "#Earnings ABBV Q3: Rev. $15.78B +9% YoY; EPS $XXXX (vs $XXXX est) XOM Q3: Rev. $85.29B (vs $86.8B est); EPS $XXXX (vs $XXXX est) LYB Q3: Rev. $10.4B -X% YoY; EPS $XXXX (vs $XXXX est) Next: Pfizer AMD Nov X Procter & Gamble Coca-Cola Nov 3-4 IBM RTX Nov 4" [X Link](https://x.com/CXL_LAB/status/1984338593209303406) [@CXL_LAB](/creator/x/CXL_LAB) 2025-10-31T19:16Z 2466 followers, 1836 engagements "$ABBV 🦉 AbbVie Reports Third-Quarter 2025 Financial Results AbbVie Q3 revenue rose XXX% to $15.78B led by Skyrizi ($4.7B) and Rinvoq ($2.18B). Adjusted EPS fell XX% to $1.86; dividend up XXX% for 2026. #newsrelease" [X Link](https://x.com/AponiaAnalytics/status/1984291661439189083) [@AponiaAnalytics](/creator/x/AponiaAnalytics) 2025-10-31T16:09Z 5163 followers, XX engagements "$ABBV AbbVie just dropped monstrous Q3 results 💥 💰Revenue: $15.78B (+9.1% YoY) 📈EPS: $XXXX (beat by $0.08) Rinvoq +35% Skyrizi +47% both now offset Humiras decline. ❗AbbVie isnt just surviving post-Humira. Its reinventing itself --expanding into immuno-oncology with Elahere Epkinly and two new acquisitions: Capstan & Nimble. Skyrizi + Rinvoq = the new cash cows. My full breakdown: #Pharma #Investing #Biotech" [X Link](https://x.com/ALLKAResearch/status/1984279504953483632) [@ALLKAResearch](/creator/x/ALLKAResearch) 2025-10-31T15:21Z XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"ABBVIE Q3 2025: ADJUSTED EPS $XXXX ON $15.78B REVENUE; RINVOQ AND SKYRIZI DRIVE GROWTH HUMIRA SALES FALL ON LOSS OF EXCLUSIVITY; FY2025 ADJUSTED EPS GUIDANCE RAISED TO $10.61-$10.65"
X Link @MultibaggAIUS 2025-10-31T21:37Z XX followers, XX engagements
"#Earnings ABBV Q3: Rev. $15.78B +9% YoY; EPS $XXXX (vs $XXXX est) XOM Q3: Rev. $85.29B (vs $86.8B est); EPS $XXXX (vs $XXXX est) LYB Q3: Rev. $10.4B -X% YoY; EPS $XXXX (vs $XXXX est) Next: Pfizer AMD Nov X Procter & Gamble Coca-Cola Nov 3-4 IBM RTX Nov 4"
X Link @CXL_LAB 2025-10-31T19:16Z 2466 followers, 1836 engagements
"$ABBV 🦉 AbbVie Reports Third-Quarter 2025 Financial Results AbbVie Q3 revenue rose XXX% to $15.78B led by Skyrizi ($4.7B) and Rinvoq ($2.18B). Adjusted EPS fell XX% to $1.86; dividend up XXX% for 2026. #newsrelease"
X Link @AponiaAnalytics 2025-10-31T16:09Z 5163 followers, XX engagements
"$ABBV AbbVie just dropped monstrous Q3 results 💥 💰Revenue: $15.78B (+9.1% YoY) 📈EPS: $XXXX (beat by $0.08) Rinvoq +35% Skyrizi +47% both now offset Humiras decline. ❗AbbVie isnt just surviving post-Humira. Its reinventing itself --expanding into immuno-oncology with Elahere Epkinly and two new acquisitions: Capstan & Nimble. Skyrizi + Rinvoq = the new cash cows. My full breakdown: #Pharma #Investing #Biotech"
X Link @ALLKAResearch 2025-10-31T15:21Z XXX followers, XXX engagements
/topic/$1578b/posts